MEDTRONIC'S TRANSFORM CARDIOMYOSTIMULATOR IMPROVES SYSTOLIC CARDIAC FUNCTION
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC'S TRANSFORM CARDIOMYOSTIMULATOR IMPROVES SYSTOLIC CARDIAC FUNCTION, investigators concluded in reporting results of a Phase II study of the device. Results from the 68-patient trial, presented at the American Heart Association's Scientific Sessions in Dallas, showed that at 12 months, left ventricular ejection fraction had increased by 15%, stroke volume by 18%, and left ventricular work index by 27%.